Jump to content

5-MeO-DPT: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
Tweaks.
 
(29 intermediate revisions by 24 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{no footnotes|date=June 2013}}
{{cs1 config|name-list-style=vanc}}
{{Drugbox
{{Drugbox
| Verifiedfields = changed
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 477224958
| verifiedrevid = 477224958
| IUPAC_name = N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-propylpropan-1-amine
| IUPAC_name = N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-propylpropan-1-amine
| image = 5-MeO-DPT chemical structure.png
| image = 5-MeO-DPT.svg
| width = 160
| width = 220
| image2 = 5-MeO-DPT.png
| width2 = 220


<!--Clinical data-->
<!--Clinical data-->
Line 14: Line 18:
| legal_AU =
| legal_AU =
| legal_CA =
| legal_CA =
| legal_UK =
| legal_DE = NpSG
| legal_US =
| legal_UK = Class A
| legal_US = [[List of Schedule I drugs (US)|Schedule I (isomer of 5-MeO-DIPT)]]
| legal_status =
| legal_status =
| routes_of_administration =
| routes_of_administration =


<!--Pharmacokinetic data-->
<!--Pharmacokinetic data-->
Line 24: Line 29:
| metabolism =
| metabolism =
| elimination_half-life =
| elimination_half-life =
| excretion =
| excretion =


<!--Identifiers-->
<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 2427-80-7
| CAS_number = 69496-75-9

| ATC_prefix =
| ATC_prefix =
| ATC_suffix =
| ATC_suffix =
| PubChem =
| PubChem = 14011047
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 14106484
| ChemSpiderID = 14106484
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 169328
| ChEMBL = 169328
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = AYW60P516B
| synonyms = 5-Methoxy-''N'',''N''-dipropyltryptamine


<!--Chemical data-->
<!--Chemical data-->
| C=17 | H=26 | N=2 | O=1
| C=17 | H=26 | N=2 | O=1
| SMILES = CCCN(CCC)CCc2c[nH]c1ccc(cc12)OC
| molecular_weight = 274.40 g/mol
| smiles = CCCN(CCC)CCc2cnc1ccc(cc12)OC
| InChI = 1/C17H26N2O/c1-4-9-19(10-5-2)11-8-14-13-18-17-7-6-15(20-3)12-16(14)17/h6-7,12-13,18H,4-5,8-11H2,1-3H3
| InChIKey = PNHPVNBKLQWBKH-UHFFFAOYAN
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C17H26N2O/c1-4-9-19(10-5-2)11-8-14-13-18-17-7-6-15(20-3)12-16(14)17/h6-7,12-13,18H,4-5,8-11H2,1-3H3
| StdInChI = 1S/C17H26N2O/c1-4-9-19(10-5-2)11-8-14-13-18-17-7-6-15(20-3)12-16(14)17/h6-7,12-13,18H,4-5,8-11H2,1-3H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = PNHPVNBKLQWBKH-UHFFFAOYSA-N
| StdInChIKey = PNHPVNBKLQWBKH-UHFFFAOYSA-N

<!--Physical data-->
| melting_point = 193
| melting_point = 193
| melting_high = 194
| melting_high = 194
}}
}}

'''5-MeO-DPT''' (also known as 5-[[methoxy]]-N,N-[[Propyl|Dipropyl]][[tryptamine]]), is a [[Psychedelic_drug|psychedelic]] and [[Entheogen|entheogenic]] drug.
'''5-MeO-DPT''', also known as '''5-methoxy-''N'',''N''-dipropyltryptamine''', is a [[psychedelic drug|psychedelic]] and [[entheogen]]ic [[designer drug]] of the [[substituted tryptamine|tryptamine]] family related to [[dipropyltryptamine]] (DPT) and [[5-MeO-DMT]].<ref name="pmid6776558">{{cite journal | vauthors = Glennon RA, Young R, Rosecrans JA, Kallman MJ | title = Hallucinogenic agents as discriminative stimuli: a correlation with serotonin receptor affinities | journal = Psychopharmacology | volume = 68 | issue = 2 | pages = 155–8 | date = 1980 | pmid = 6776558 | doi = 10.1007/BF00432133 | s2cid = 1674481 }}</ref><ref>{{cite journal | vauthors = Nakamoto A, Namera A, Nishida M, Yashiki M, Kuramoto T, Kimura K | title = Identification and quantitative determination of 5-methoxy-N, N-di-n-propyltryptamine in urine by isotope dilution gas chromatography-mass spectrometry. | journal = Forensic Toxicology | date = June 2007 | volume = 25 | issue = 1 | pages = 1–7 | doi = 10.1007/s11419-006-0018-y | s2cid = 9906203 }}</ref><ref>{{cite journal | vauthors = Nakazono Y, Tsujikawa K, Kuwayama K, Kanamori T, Iwata YT, Miyamoto K, Kasuya F, Inoue H | title = Simultaneous determination of tryptamine analogues in designer drugs using gas chromatography–mass spectrometry and liquid chromatography–tandem mass spectrometry. | journal = Forensic Toxicology | date = January 2014 | volume = 32 | issue = 1 | pages = 154–61 | doi = 10.1007/s11419-013-0208-3 | s2cid = 25134125 }}</ref><ref name="pmid34026257">{{cite journal | vauthors = Pham DN, Chadeayne AR, Golen JA, Manke DR | title = 5-Meth-oxy-N,N-di-n-propyl-tryptamine (5-MeO-DPT): freebase and fumarate | journal = Acta Crystallographica Section E | volume = 77 | issue = Pt 5 | pages = 522–526 | date = May 2021 | pmid = 34026257 | pmc = 8100262 | doi = 10.1107/S2056989021003753 | bibcode = 2021AcCrE..77..522P }}</ref>


==Chemistry==
==Chemistry==
The full chemical name is N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-propylpropan-1-amine. It is classified as a [[tryptamine]] [[Chemical_derivative|derivative]].
The full chemical name is ''N''-[2-(5-methoxy-1''H''-indol-3-yl)ethyl]-''N''-propylpropan-1-amine. It is classified as a [[substituted tryptamine|tryptamine]] [[chemical derivative|derivative]].


==Effects==
==Effects==
Little is known about the subjective effects of 5-MeO-DPT, but the nature of the compound is probably comparable to [[psilocybin]]/[[psilocin]], or [[DPT]], which are also [[psychedelic drugs|psychedelic]] tryptamines/indoles. However, the duration of the above mentioned drugs vary considerably.
Little is known about the subjective effects of 5-MeO-DPT, but the nature of the compound is probably comparable to [[5-MeO-DiPT]], [[5-MeO-DMT]], or [[Dipropyltryptamine|DPT]], which are also [[psychedelic drugs|psychedelic]] tryptamines/indoles. However, the duration of the above-mentioned drugs vary considerably.


==Dosage==
==Dosage==
5-MeO-DPT is [[Wiktionary:oral|oral]]ly active, with 3-10 [[milligram|mg]] representing a fully effective dosage for most users. Effects begin within three hours, and usually last 4 hours.
5-MeO-DPT is [[Wiktionary:oral|oral]]ly active, with 3-10 [[milligram|mg]] representing a fully effective dosage for most users. Effects begin within three hours, and usually last 4 hours.

==Legality==
In the United States 5-MeO-DPT is considered a schedule 1 controlled substance as a positional isomer of [[5-Methoxy-N,N-diisopropyltryptamine]] (5-MeO-DiPT)<ref>{{cite web |url=https://www.deadiversion.usdoj.gov/schedules/orangebook/orangebook.pdf|title=Lists of: Scheduling Actions Controlled Substances Regulated Chemicals|publisher=U.S. Department of Justice|date=February 2023
|access-date=5 March 2023}}</ref>

==See also==
* [[5-MeO-DALT]]
* [[5-MeO-DET]]
* [[5-MeO-DBT]]
* [[5-MeO-EPT]]


==References==
==References==
Line 72: Line 91:
{{Tryptamines}}
{{Tryptamines}}


[[Category:Phenol ethers]]
[[Category:Mexamines]]
[[Category:Psychedelic tryptamines]]
[[Category:Psychedelic tryptamines]]
[[Category:Designer drugs]]
[[Category:Designer drugs]]



{{hallucinogen-stub}}
{{hallucinogen-stub}}

Latest revision as of 19:30, 10 November 2024

5-MeO-DPT
Clinical data
Other names5-Methoxy-N,N-dipropyltryptamine
Legal status
Legal status
Identifiers
  • N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-propylpropan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H26N2O
Molar mass274.408 g·mol−1
3D model (JSmol)
Melting point193 to 194 °C (379 to 381 °F)
  • CCCN(CCC)CCc2c[nH]c1ccc(cc12)OC
  • InChI=1S/C17H26N2O/c1-4-9-19(10-5-2)11-8-14-13-18-17-7-6-15(20-3)12-16(14)17/h6-7,12-13,18H,4-5,8-11H2,1-3H3 checkY
  • Key:PNHPVNBKLQWBKH-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

5-MeO-DPT, also known as 5-methoxy-N,N-dipropyltryptamine, is a psychedelic and entheogenic designer drug of the tryptamine family related to dipropyltryptamine (DPT) and 5-MeO-DMT.[1][2][3][4]

Chemistry

[edit]

The full chemical name is N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-propylpropan-1-amine. It is classified as a tryptamine derivative.

Effects

[edit]

Little is known about the subjective effects of 5-MeO-DPT, but the nature of the compound is probably comparable to 5-MeO-DiPT, 5-MeO-DMT, or DPT, which are also psychedelic tryptamines/indoles. However, the duration of the above-mentioned drugs vary considerably.

Dosage

[edit]

5-MeO-DPT is orally active, with 3-10 mg representing a fully effective dosage for most users. Effects begin within three hours, and usually last 4 hours.

Legality

[edit]

In the United States 5-MeO-DPT is considered a schedule 1 controlled substance as a positional isomer of 5-Methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT)[5]

See also

[edit]

References

[edit]
  1. ^ Glennon RA, Young R, Rosecrans JA, Kallman MJ (1980). "Hallucinogenic agents as discriminative stimuli: a correlation with serotonin receptor affinities". Psychopharmacology. 68 (2): 155–8. doi:10.1007/BF00432133. PMID 6776558. S2CID 1674481.
  2. ^ Nakamoto A, Namera A, Nishida M, Yashiki M, Kuramoto T, Kimura K (June 2007). "Identification and quantitative determination of 5-methoxy-N, N-di-n-propyltryptamine in urine by isotope dilution gas chromatography-mass spectrometry". Forensic Toxicology. 25 (1): 1–7. doi:10.1007/s11419-006-0018-y. S2CID 9906203.
  3. ^ Nakazono Y, Tsujikawa K, Kuwayama K, Kanamori T, Iwata YT, Miyamoto K, Kasuya F, Inoue H (January 2014). "Simultaneous determination of tryptamine analogues in designer drugs using gas chromatography–mass spectrometry and liquid chromatography–tandem mass spectrometry". Forensic Toxicology. 32 (1): 154–61. doi:10.1007/s11419-013-0208-3. S2CID 25134125.
  4. ^ Pham DN, Chadeayne AR, Golen JA, Manke DR (May 2021). "5-Meth-oxy-N,N-di-n-propyl-tryptamine (5-MeO-DPT): freebase and fumarate". Acta Crystallographica Section E. 77 (Pt 5): 522–526. Bibcode:2021AcCrE..77..522P. doi:10.1107/S2056989021003753. PMC 8100262. PMID 34026257.
  5. ^ "Lists of: Scheduling Actions Controlled Substances Regulated Chemicals" (PDF). U.S. Department of Justice. February 2023. Retrieved 5 March 2023.
[edit]